Physician profile
Rohit Kumar
NPI 1154737724
$30,898.32
in general payments reported to CMS, 2019-2025
58 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,419 · 2020: $1,867 · 2021: $1,364 · 2022: $1,033 · 2023: $1,067 · 2024: $6,161 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,573 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,550 · Food and Beverage: $5,863 · Honoraria: $1,110 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,572.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,550.00 |
| Food and Beverage | $5,863.28 |
| Honoraria | $1,110.00 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $8,360.11 | 2019-2025 | |
| Emd Serono, INC. | $2,985.14 | 2020-2025 | Tepmetko |
| Springworks Therapeutics, INC. | $2,367.49 | 2024-2025 | Ogsiveo, Gomekli |
| Amgen INC. | $2,364.12 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Astrazeneca Pharmaceuticals Lp | $2,350.57 | 2019-2025 | Imfinzi, Truqap, Lynparza |
| Deciphera Pharmaceuticals INC. | $1,143.89 | 2021-2025 | Vimseltinib |
| Janssen Biotech, INC. | $1,083.74 | 2019-2024 | Erleada |
| Merck Sharp & Dohme LLC | $1,032.50 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $943.30 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Eisai INC. | $886.88 | 2019-2025 | |
| Celgene Corporation | $827.42 | 2019-2025 | Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $659.13 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $616.59 | 2019-2025 | Opdivo |
| Novo Nordisk INC | $501.04 | 2020 | |
| Astellas Pharma US INC | $489.27 | 2019-2025 | Xtandi, Padcev, Vyloy |
Show all 56 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.